Abstract

The intestinal immune response is crucial in maintaining a healthy gut, but the enhanced migration of macrophages in response to pathogens is a major contributor to disease pathogenesis. Integrins are ubiquitously expressed cellular receptors that are highly involved in immune cell adhesion to endothelial cells while in the circulation and help facilitate extravasation into tissues. Here we show that specific deletion of the Tln1 gene encoding the protein talin-1, an integrin-activating scaffold protein, from cells of the myeloid lineage using the Lyz2-cre driver mouse reduces epithelial damage, attenuates colitis, downregulates the expression of macrophage markers, decreases the number of differentiated colonic mucosal macrophages, and diminishes the presence of CD68-positive cells in the colonic mucosa of mice infected with the enteric pathogen Citrobacter rodentium. Bone marrow-derived macrophages lacking expression of Tln1 did not exhibit a cell-autonomous phenotype; there was no impaired proinflammatory gene expression, nitric oxide production, phagocytic ability, or surface expression of CD11b, CD86, or major histocompatibility complex II in response to C. rodentium. Thus, we demonstrate that talin-1 plays a role in the manifestation of infectious colitis by increasing mucosal macrophages, with an effect that is independent of macrophage activation.

Details

Title
Myeloid deletion of talin-1 reduces mucosal macrophages and protects mice from colonic inflammation
Author
Latour, Yvonne L. 1 ; McNamara, Kara M. 2 ; Allaman, Margaret M. 3 ; Barry, Daniel P. 3 ; Smith, Thaddeus M. 3 ; Asim, Mohammad 3 ; Williams, Kamery J. 3 ; Hawkins, Caroline V. 3 ; Jacobse, Justin 1 ; Goettel, Jeremy A. 4 ; Delgado, Alberto G. 3 ; Piazuelo, M. Blanca 5 ; Washington, M. Kay 6 ; Gobert, Alain P. 5 ; Wilson, Keith T. 7 

 Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University Medical Center, Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916) 
 Vanderbilt University Medical Center, Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University School of Medicine, Program in Cancer Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217) 
 Vanderbilt University Medical Center, Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916) 
 Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University Medical Center, Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University School of Medicine, Program in Cancer Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); Vanderbilt University Medical Center, Center for Mucosal Inflammation and Cancer, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916) 
 Vanderbilt University Medical Center, Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University Medical Center, Center for Mucosal Inflammation and Cancer, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916) 
 Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University Medical Center, Center for Mucosal Inflammation and Cancer, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916) 
 Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University Medical Center, Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University School of Medicine, Program in Cancer Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); Vanderbilt University Medical Center, Center for Mucosal Inflammation and Cancer, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Veterans Affairs Tennessee Valley Healthcare System, Nashville, USA (GRID:grid.452900.a) (ISNI:0000 0004 0420 4633) 
Pages
22368
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2902171830
Copyright
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.